According to a new report published by the Transparency Market Research (TMR) called “Erectile Dysfunction Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026,” the global erectile dysfunction market was valued at $4.35 billion in 2016, which is estimated to decline at a Compound Annual Growth Rate (CAGR) of 3.2 percent from 2018 to 2026.
The report has stated that the global market is expected to decline from 2018 to 2026 due to patent expiration. For instance, Bayer’s Levitra/Staxyn (vardenafil) will expire in 2018, contributing to the decline in revenue.
However, the high prevalence and increasing incidence rate of erectile dysfunction and patient compliance are expected to increase the sales in the erectile dysfunction drugs market from 2018 to 2026.
In 2017, North America had the largest share of the global erectile dysfunction drugs market. America is the largest pharmaceutical market in the world, accounting for more than 95 percent of the market in North America.
In the United States, the erectile dysfunction drugs market is driven by the availability of brand-name impotence drugs such as Viagra (sildenafil), Levitra/Staxyn (vardenafil), and Cialis (tadalafil). However, their patents are going to expire soon, altering this scenario by the end of 2026.
According to surveys, more than 50 million men suffer from erectile dysfunction in the United States. The incidence rate of impotence has increased from 5 percent among men 40 years old to 15 percent among men 70 years old.
The prevalence rate is expected to increase due to rise in geriatric people and the incidence rate will increase due to medical conditions such as cardiovascular diseases, diabetes, and hypercholesterolemia, which are responsible for causing erectile dysfunction.
Pfizer and Eli Lilly are the leading global players in the erectile dysfunction market, recording the highest sales for Viagra and Cialis, respectively, along with Bayer (Staxyn).
Viagra, Cialis, and Levitra/Staxyn belong to the same class of drugs called phosphodiesterase-5 (PDE5) inhibitors. Among them, Viagra is the most popular drug sold across the world. Viagra is expected to lead the share of the global erectile dysfunction market during the forecast period. Also, the retail pharmacies are expected to dominate the market during the forecast period.E Easy availability and cost-effectiveness of these drugs at retail and online pharmacies will drive the market.
